Centre Léon Bérard
Centre Léon Bérard
Lyon, France50 results · Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 1 / Phase 2 | 2026-10-09 | NCT03424005 | |
| A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer | Metastatic Castration-Resistant Prostate Cancer | Recruiting | Phase 2 | 2026-10-08 | NCT07287150 | |
| A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, metastatic prostate carcinoma, neoplasm, prostate cancer, prostate disorder | Recruiting | Phase 1 | 2026-10-06 | NCT05800665 | |
| Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors | Digestive System Diseases, Digestive System Neoplasms, Neoplasm Metastasis, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, Thoracic Neoplasms, breast disorder, breast neoplasm, bronchial neoplasm, bronchogenic carcinoma, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, rectal disorder, respiratory system disorder, respiratory tract neoplasm, skin disorder | Recruiting | Phase 1 | 2026-10-01 | NCT06625775 | |
| A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03) | Extensive Stage-small Cell Lung Cancer | Recruiting | Phase 1 / Phase 2 | 2026-10-01 | NCT06362252 | |
| A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors | Adnexal Diseases, Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Head and Neck Neoplasms, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Pancreatic Carcinoma, Skin and Connective Tissue Diseases, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, benign urinary system neoplasm, breast cancer, breast disorder, breast neoplasm, bronchial neoplasm, bronchogenic carcinoma, cervix disorder, digestive system disorder, digestive system neoplasm, endocrine system disorder, endometrium neoplasm, esophageal cancer, esophageal disorder, female reproductive system disorder, female reproductive system neoplasm, gastric cancer, gastric neoplasm, gonadal disorder, head and neck cancer, lung cancer, lung disorder, lung neoplasm, male reproductive organ cancer, male reproductive system disorder, malignant endocrine neoplasm, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, non-small cell lung carcinoma, ovarian cancer, ovarian carcinoma, ovarian disorder, pancreas disorder, pancreatic neoplasm, primitive neuroectodermal tumor, prostate cancer, prostate disorder, respiratory system disorder, respiratory tract neoplasm, skin disorder, skin neoplasm, stomach disorder, urinary bladder cancer, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder, uterine disorder | Recruiting | Phase 2 | 2026-10-01 | NCT06172478 | |
| First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors | Neoplasm Metastasis, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-09-29 | NCT05875168 | |
| NP137 Clinical and Biological Activities Assessment in Patients With Advanced/Metastatic Solid Tumors Treated by Standard Anti PD-1/PD-L1 Immunotherapies | Advanced Solid Tumors; Metastatic Solid Tumors | Active, not recruiting | Phase 2 | 2026-09-25 | NCT05605496 | |
| Immunotherapy in MSI/dMMR Tumors in Perioperative Setting. | neoplasm | Active, not recruiting | Phase 2 | 2026-09-10 | NCT04795661 | |
| Iatrogenic Effects of Treatment for Childhood Cancer Constitution of a Biological Samples Bank | Paediatric Malignancies | Recruiting | Not stated | 2026-09-10 | NCT02666625 | |
| Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-09-02 | NCT06567015 | |
| R-GASTIM- Study of Gastric Cancer Operable | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, digestive system disorder, digestive system neoplasm, gastric cancer, gastric neoplasm, neoplasm, stomach disorder | Recruiting | Not stated | 2026-08-26 | NCT07787052 | |
| A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm, small cell lung carcinoma | Recruiting | Phase 3 | 2026-08-06 | NCT06203210 | |
| Detecting Tumor DNA in the Blood of HR+/HER2-low Metastatic Breast Cancer Patients to Find Candidates for T-DXd Therapy | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Enrolling by invitation | Phase 2 | 2026-08-03 | NCT06680596 | |
| Optimising Adjuvant Chemotherapy Prescription in Young Patients With Hormone-dependent Breast Cancer Using Genomic Tests | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 3 | 2026-07-31 | NCT07106632 | |
| Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors | Adnexal Diseases, Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Head and Neck Neoplasms, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, breast disorder, breast neoplasm, bronchial neoplasm, bronchogenic carcinoma, carcinoma, cervix disorder, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, endocrine system disorder, epithelial neoplasm, esophageal disorder, esophageal squamous cell carcinoma, female reproductive system disorder, female reproductive system neoplasm, gastric neoplasm, gonadal disorder, head and neck squamous cell carcinoma, intestinal disorder, lung disorder, lung neoplasm, male reproductive organ cancer, male reproductive system disorder, malignant endocrine neoplasm, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, non-small cell lung carcinoma, ovarian cancer, ovarian disorder, primitive neuroectodermal tumor, prostate cancer, prostate disorder, rectal disorder, respiratory system disorder, respiratory tract neoplasm, skin disorder, skin neoplasm, squamous cell carcinoma, squamous cell neoplasm, stomach disorder, transitional cell carcinoma, triple-negative breast carcinoma, uterine disorder | Active, not recruiting | Phase 1 | 2026-07-27 | NCT06781983 | |
| Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Recruiting | Phase 2 | 2026-07-24 | NCT06078384 | |
| Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Active, not recruiting | Phase 3 | 2026-07-02 | NCT06578247 | |
| Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas | Digestive System Diseases, Digestive System Neoplasms, Neoplasm Metastasis, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, digestive system disorder, digestive system neoplasm, gastric cancer, gastric neoplasm, metastatic malignant neoplasm, neoplasm, stomach disorder | Recruiting | Phase 3 | 2026-06-25 | NCT06346197 | |
| Alpha Radiation Emitters Device (DaRT) for the Treatment of of Malignant Cutaneous Tumors | Facial Neoplasms, Head and Neck Neoplasms, Mouth Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Skin and Connective Tissue Diseases, Stomatognathic Diseases, basal cell carcinoma, basal cell neoplasm, carcinoma, epithelial neoplasm, eye disorder, eyelid disorder, eyelid neoplasm, lip disorder, mouth disorder, neoplasm, ocular cancer, skin disorder, skin neoplasm, squamous cell carcinoma, squamous cell neoplasm | Recruiting | Not applicable | 2026-06-16 | NCT04068155 | |
| Assessment of Retreatment With Lutathera® in Patients With New Progression of Intestinal Well-differenciated NET | Disease Attributes, Disease Progression, Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Pathologic Processes, Pathological Conditions, Signs and Symptoms, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor | Recruiting | Phase 2 | 2026-06-04 | NCT04954820 | |
| Locoregional Treatment and Palbociclib in de Novo, Treatment Naive, Stage IV ER+, HER2- Breast Cancer Patients | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Not applicable | 2026-05-20 | NCT03870919 | |
| Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors | Adnexal Diseases, Carcinoma, Ductal, Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Ductal, Lobular, and Medullary, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, appendiceal neoplasm, bronchial disorder, bronchial neoplasm, bronchogenic carcinoma, carcinoma, cecal disorder, cecal neoplasm, colonic disorder, colonic neoplasm, colorectal neoplasm, digestive system disorder, digestive system neoplasm, endocrine system disorder, endometrium neoplasm, epithelial neoplasm, esophageal disorder, female reproductive system disorder, female reproductive system neoplasm, gastric neoplasm, gonadal disorder, intestinal disorder, lung disorder, lung neoplasm, malignant endocrine neoplasm, neoplasm, non-small cell lung carcinoma, ovarian cancer, ovarian disorder, pancreas disorder, pancreatic ductal adenocarcinoma, pancreatic neoplasm, rectal disorder, rectal neoplasm, respiratory system disorder, respiratory tract neoplasm, stomach disorder, uterine disorder | Active, not recruiting | Phase 1 | 2026-05-15 | NCT05462717 | |
| DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2) | Noonan syndrome 5, low grade glioma | Active, not recruiting | Phase 3 | 2026-05-14 | NCT05566795 | |
| Heterogeneity of Oral Carcinogenesis: From PrEneoplasia to Invasive Squamous Cell Carcinoma | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Oral Squamous Cell Carcinoma, carcinoma, epithelial neoplasm, head and neck squamous cell carcinoma, neoplasm, squamous cell carcinoma | Not yet recruiting | Not applicable | 2026-05-12 | NCT07579507 |